Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. (NAGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July Launched Niagen Plus telehealth platform Net sales of $29.8 million, including $24.2 million from Tru Niagen G
How this was made
The 30-second read
Why it matters
Traders can reassess near-term fundamentals using the reported Q2 financials and cash flow, while also repricing longer-dated optionality from FDA/EMA designations for NB4168 and the telehealth platform launch.
Market read
A single filing updates both the income statement and the development/commercial roadmap, creating multiple potential drivers for sentiment and positioning.
What to watch
Investors may discount the pipeline progress until IND-enabling milestones begin in Q3 2026 and until 2027 contributions from Niagen Plus and new skincare partnerships become measurable.
Background
Niagen Bioscience filed an 8-K with Q2 2026 results and operational updates, including commercialization expansion and a new investigational therapeutic candidate.
Ticker impact
Niagen reported Q2 2026 net sales of $29.8M, $1.0M net income, and launched Niagen Plus telehealth plus an NB4168 rare-disease program.
Near-term volatility likely, with upside bias if investors focus on cash generation, telehealth traction, and regulatory designations; downside risk if ingredient business softness and higher opex are emphasized.
This is a primary disclosure with multiple fresh datapoints: Q2 financials, cash balance, buyback, telehealth launch with LegitScript certification, and new regulatory designations plus CRO engagement for IND-enabling work.
Market effects
Adds a small-cap nutraceutical-to-pharma narrative catalyst, potentially influencing sentiment toward NAD+ and rare-disease development peers.
Limited, primarily US small-cap biotech/nutrition investor base.
EMA designation (OMPD) supports international development credibility, but scale remains company-specific.
Counterpoint
Telehealth and NB4168 progress may not translate into near-term revenue, while guidance implies ingredient sales headwinds and rising operating expenses.
Key entities
- issuerNiagen Bioscience, Inc.
NASDAQ-listed company reporting Q2 2026 results, cash position, buyback, and updates on Niagen Plus and NB4168.
- pipeline_assetNB4168
Oral small-molecule investigational therapeutic targeting rare genetic diseases and aging-related disorders, initially Ataxia-Telangiectasia.
- crosEvotec
Contract research organization engaged for preclinical and IND-enabling studies for NB4168 starting anticipated Q3 2026.
- regulatorU.S. Food and Drug Administration
Granted Rare Pediatric Disease designation for NB4168 for Ataxia-Telangiectasia.
- regulatorEuropean Medicines Agency
Granted Orphan Medicinal Product designation for NB4168.
